Suchergebnisse - "Cook, Gordon"

PubPharm (409)

91

Clinical features associated with COVID-19 outcome in multiple myeloma : first results from the International Myeloma Society data set

enthalten in: Blood | 2020

von Chari, A. | Samur, M. | Martinez-Lopez, J. | +22

92

Outcomes of patients with hematologic malignancies and COVID-19 : a systematic review and meta-analysis of 3377 patients

enthalten in: Blood | 2020

von Vijenthira, A. | Gong, I. | Fox, T. | +16

CommentIn: Blood. 2020 Dec 17;136(25):2844-2845. - PMID 33331931

93

Evolution or revolution in multiple myeloma therapy and the role of the UK

enthalten in: British journal of haematology | 2020

von Cook, G. | Morris, C.

94

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

enthalten in: Blood cancer journal | 2020

von Kaufman, J. | Dimopoulos, M. | White, D. | +26

95

Predicting ultrahigh risk multiple myeloma by molecular profiling : an analysis of newly diagnosed transplant eligible myeloma XI trial patients

enthalten in: Leukemia | 2020

von Shah, V. | Sherborne, A. | Johnson, D. | +41

96

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

enthalten in: Blood cancer journal | 2020

von Hoang, P. | Cornish, A. | Sherborne, A. | +8

97

The MUK eight protocol : a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

enthalten in: Trials | 2020

von Hinsley, S. | Walker, K. | Sherratt, D. | +13

98

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

enthalten in: Trials | 2020

von Hinsley, S. | Walker, K. | Sherratt, D. | +12

99

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

enthalten in: Trials | 2020

von Hinsley, S. | Walker, K. | Sherratt, D. | +12

100

Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network

enthalten in: Leukemia | 2020

von Cook, G. | Larocca, A. | Facon, T. | +2